Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Tax Provisions (2018 - 2025)

10x Genomics (TXG) has disclosed Tax Provisions for 8 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 63.43% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 26.18% year-over-year, with the annual reading at $3.6 million for FY2025, 26.18% down from the prior year.
  • Tax Provisions hit $1.1 million in Q4 2025 for 10x Genomics, up from -$733000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.5 million in Q2 2025 to a low of -$733000.0 in Q3 2025.
  • Historically, Tax Provisions has averaged $1.2 million across 5 years, with a median of $1.1 million in 2023.
  • Biggest five-year swings in Tax Provisions: soared 259.27% in 2022 and later crashed 155.74% in 2025.
  • Year by year, Tax Provisions stood at $2.5 million in 2021, then tumbled by 67.26% to $804000.0 in 2022, then surged by 192.79% to $2.4 million in 2023, then crashed by 72.47% to $648000.0 in 2024, then soared by 63.43% to $1.1 million in 2025.
  • Business Quant data shows Tax Provisions for TXG at $1.1 million in Q4 2025, -$733000.0 in Q3 2025, and $2.5 million in Q2 2025.